Clinical Trials on Fibrodyplasia Ossificans Progressiva (FOP)
Total 24 results
-
Regeneron PharmaceuticalsWithdrawnFibrodyplasia Ossificans Progressiva (FOP) | Heterotopic Ossification (HO)
-
IpsenActive, not recruitingFibrodysplasia Ossificans Progressiva (FOP)United States, France, Australia, Argentina, Italy, Canada, Sweden, United Kingdom, Brazil, Spain
-
Incyte CorporationRecruitingFibrodysplasia Ossificans Progressiva (FOP)United States, France, Korea, Republic of, Spain, Italy, United Kingdom, Russian Federation, China, Australia, Brazil, Mexico, New Zealand, Argentina, Canada, Netherlands, Turkey, Chile, Germany, South Africa, Portugal
-
The International FOP AssociationRecruitingFibrodysplasia Ossificans Progressiva (FOP)United States
-
Regeneron PharmaceuticalsCompletedFibrodysplasia Ossificans Progressiva (FOP)United States
-
Clementia Pharmaceuticals Inc.CompletedFibrodysplasia Ossificans ProgressivaUnited States, Canada, France, Australia, Argentina, Brazil, Italy, Japan, Spain, Sweden, United Kingdom
-
Clementia Pharmaceuticals Inc.TerminatedFibrodysplasia Ossificans ProgressivaUnited States
-
IpsenNot yet recruiting
-
Clementia Pharmaceuticals Inc.IpsenRecruitingFibrodysplasia Ossificans ProgressivaUnited States, Korea, Republic of, Belgium, China, Sweden, France, Japan, Argentina, Australia, Brazil, Canada, Italy, Spain, United Kingdom, Mexico, Colombia, Netherlands, Germany, Portugal
-
Daiichi Sankyo Co., Ltd.CompletedFibrodysplasia Ossificans ProgressivaJapan
-
Clementia Pharmaceuticals Inc.CompletedFibrodysplasia Ossificans ProgressivaUnited States
-
Regeneron PharmaceuticalsCompletedFibrodysplasia Ossificans ProgressivaUnited States, Spain, Canada, France, Poland, Italy, Netherlands, United Kingdom
-
IpsenCompletedFibrodysplasia Ossificans ProgressivaUnited States
-
Novartis PharmaceuticalsCompleted
-
Regeneron PharmaceuticalsRecruitingFibrodysplasia Ossificans ProgressivaJapan, United States, Korea, Republic of, Spain, France, Australia, United Kingdom, China, Poland, Malaysia, Italy, Finland, Hong Kong, South Africa, Chile, Brazil, Netherlands, Colombia
-
Clementia Pharmaceuticals Inc.CompletedFibrodysplasia Ossificans ProgressivaUnited States, France, United Kingdom
-
Clementia Pharmaceuticals Inc.CompletedFibrodysplasia Ossificans ProgressivaUnited States, Argentina, Australia, France, United Kingdom
-
Clementia Pharmaceuticals Inc.CompletedFibrodysplasia Ossificans ProgressivaFrance
-
Clementia Pharmaceuticals Inc.CompletedFibrodysplasia Ossificans ProgressivaUnited States, Argentina, Australia, France, United Kingdom, Italy
-
Amsterdam UMC, location VUmcAstraZeneca; Brigham and Women's Hospital; University of Oxford; Klinikum Garmisch-Patenkirchen and other collaboratorsRecruitingFibrodysplasia Ossificans ProgressivaGermany, Netherlands, United Kingdom
-
Latin American Cooperative Oncology GroupGlaxoSmithKlineCompletedBRMS1 | Performance Status Zero to Two for Beginning the Study | Patient With a Maximum of One Chemotherapy | Patient With Progression After TaxanesArgentina, Brazil, Peru
-
Sehit Prof. Dr. Ilhan Varank Sancaktepe Training...Active, not recruitingProgression | Ultrasound Therapy; Complications | Labour;Obstructed | Delivery Problem for FetusTurkey
-
Gigi VeeremanCompletedDescription of Disease Course, Disease Fenotype, Medication, Safety, Analysis for Possible AssociationsBelgium
-
Peking University People's HospitalPeking University; Northwestern University; University of ChicagoUnknownHistologic Response (Tumor Necrosis Rate) | Objective Response Rate for Neoadjuvant Chemotherapy, ORR | Progression-free Survival, PFS | Overall Survival, OSChina